Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Pulmonary Arterial Hypertension: An Overview
*Corresponding Author:Received Date: Nov 01, 2024 / Published Date: Nov 30, 2024
Copyright: © 0 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Pulmonary arterial hypertension (PAH) is a severe and progressive disorder characterized by elevated pulmonary arterial pressure, leading to right ventricular failure and reduced exercise capacity. This overview examines the pathophysiology, clinical presentation, diagnostic methods, and management strategies of PAH. The condition can be idiopathic or secondary to various underlying diseases, with a complex interplay of genetic, environmental, and hemodynamic factors contributing to its progression. Early diagnosis is critical, often facilitated by echocardiography and right heart catheterization. Current treatment options include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs, aimed at improving patient outcomes. Recent research is focusing on novel therapeutic targets and combination therapies, highlighting the importance of personalized management strategies. Understanding PAH’s multifaceted nature is essential for improving prognosis and enhancing quality of life for affected individuals.
